137178-88-2

Usage

Chemical Properties

Brown solid

InChI:InChI=1/C6H3BrClNO/c7-4-1-2-5(6(8)10)9-3-4/h1-3H

Upstream product

• 30766-11-1 5-bromoisonicotinic acid 
• 29682-15-3 methyl 5-bromopicolinate 
• 3430-13-5 5-bromo-2-methylpyridine 
• 624-28-2 2,5-dibromopyridine 
• 97483-77-7 2-Cyano-5-bromopyridine 

Downstream Products

• 29682-15-3 methyl 5-bromopicolinate 
• 638219-77-9 5-bromo-2-(N-cyclopropylaminocarbonyl)pyridine 
• 742085-70-7 (5-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone 
• 1113048-76-2 C₂₇H₂₆BrF₃N₄O₅ 
• 1113048-83-1 C₂₂H₁₆BrClF₃N₃O₄ 
• 1113048-84-2 C₂₃H₁₇BrF₃N₃O₄ 
• 1113049-01-6 C₂₅H₂₀BrF₃N₆O₄ 
• 77199-09-8 5-bromo-pyridine-2-carboxylic acid ethyl ester 
• 1211592-38-9 5-bromo-N-methyoxy-N-methylpyridine-2-carboxamide 
• 1365756-96-2 2-(5-bromopyridin-2-yl)-1-phenyl-1H-benzo[d]imidazole 
• 934329-37-0 2-(5-bromopyridin-2-yl)benzo[d]oxazole 
• 915394-66-0 methyl (5-bromopyridine-2-carbonyl)glycinate 
• 1610537-32-0 C₁₇H₂₀N₂O₂ 
• 951885-14-6 5-bromo-N-butylpicolinamide 

Relevant academic research and scientific papers

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors

We initiated our structure-activity relationship (SAR) studies for selective ACC1 inhibitors from 1a as a lead compound. SAR studies of bicyclic scaffolds revealed many potent and selective ACC1 inhibitors represented by 1f; however most of them had physicochemical issues, particularly low aqueous solubility and potent CYP inhibition. To address these two issues and improve the druglikeness of this chemical series, we converted the bicyclic scaffold into a monocyclic framework. Ultimately, this lead us to discover a novel monocyclic derivative 1q as a selective ACC1 inhibitor, which showed highly potent and selective ACC1 inhibition as well as acceptable solubility and CYP inhibition profiles. Since compound 1q displayed favorable bioavailability in mouse cassette dosing testing, we conducted in vivo PD studies of this compound. Oral administration of 1q significantly reduced the concentration of malonyl-CoA in HCT-116 xenograft tumors at doses of more than 30 mg/kg. Accordingly, our novel series of selective ACC1 inhibitors represents a set of useful orally available research tools, as well as potential therapeutic agents for cancer and fatty acid related diseases.

MONOCYCLIC COMPOUND

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

A 2-amino-thiazole compounds (by machine translation)

The present invention relates to the technical field of pharmaceutical chemistry, particularly relates to a 2-amino thiazole compound or its pharmaceutically acceptable salts, its preparation method, and pharmaceutical compositions containing such compounds and its application in the preparation of antineoplastic. (by machine translation)

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

TETRAHYDROXAZOROPYRIDINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a therapeutic agent for neurological disorders and neurodegenerative diseases related to mGluR5, having effects as a metabolism type glutamic acid receptor subtype 5 (mGluR5) negative modulator, having an oral absorption property excellent in pharmacokinetics, high biological availability and excellent safety. SOLUTION: There is provided a compound of the formula (I) and a pharmaceutically acceptable salt. Formula (I), where R1 represents a halogen, methyl or cyano, R2 and R3 represent each independently a hydrogen atom, halogen, C1-3 alkyl, C1-3 alkoxy or cyano. COPYRIGHT: (C)2016,JPOandINPIT

Iridium(III)-Catalyzed Regioselective Intermolecular Unactivated Secondary Csp3?H Bond Amidation

For the first time, a highly regioselective intermolecular sulfonylamidation unactivated secondary Csp3?H bond has been achieved using IrIIIcatalysts. The introduced N,N’-bichelating ligand plays a crucial role in enabling iridium–nitrene insertion into a secondary Csp3?H bond via an outer-sphere pathway. Mechanistic studies and density functional theory (DFT) calculations demonstrated that a two-electron concerted nitrene insertion was involved in this Csp3?H amidation process. This method tolerates a broad range of linear and branched-chain N-alkylamides, and provides efficient access to diverse γ-sulfonamido-substituted aliphatic amines.

Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: Exploration of diverse hinge-binding fragments

Abstract VEGFR-2 plays an essential role in angiogenesis and is an important target for cancer therapy. A series of biphenyl-aryl ureas were synthesized and evaluated as novel VEGFR-2 inhibitors. The pyridine, methylamine carbonyl pyridine and pivaloyl amide pyridine were introduced as novel hinge binding fragment. The majority of title compounds displayed potent VEGFR-2 inhibition. In particular, L1, L9, W14 and W15 exhibited significant enzymatic inhibitory activity with IC50 values of 0.36 nM, 0.22 nM, 0.15 nM and 0.14 nM. Compounds L1, L9 and W15 displayed potent antiproliferative activity against A549 and SMMC-7721 cells. SAR study suggested that incorporation of 3-trifluoromethyl and methylamine carbonyl on terminal pyridine could improve VEGFR-2 inhibitory activity. Molecular docking illustrated that urea moiety formed two critical hydrogen bonds with the DFG residues of VEGFR-2. The results indicated that these biphenyl-aryl ureas could serve as promising lead compounds for further optimization.